Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie E. Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B. Ottevanger, Jonathan A. Ledermann, Pearly Khaw, Alessandro Colombo, Anthony Fyles, Marie-Helene Baron, Ina M. Jurgenliemk-Schulz, Henry C. Kitchener, Hans W. Nijman, Godfrey Wilson, Susan Brooks, Silvestro Carinelli, Diane Provencher, Chantal HanzenLudy C. H. W. Lutgens, Vincent T. H. B. M. Smit, Naveena Singh, Viet Do, Romerai D'Amico, Remi A. Nout, Amanda Feeney, Karen W. Verhoeven-Adema, Hein Putter, Carien L. Creutzberg, PORTEC Study Grp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)295-309
Number of pages15
JournalLancet oncology
Volume19
Issue number3
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • GYNECOLOGIC-ONCOLOGY-GROUP
  • QUALITY-OF-LIFE
  • RADIATION-THERAPY
  • STAGE-I
  • CARCINOMA PATIENTS
  • CLINICAL-TRIALS
  • III TRIAL
  • CHEMOTHERAPY
  • RECURRENCE
  • PROGNOSIS
  • Lymph Node Excision
  • Chemoradiotherapy, Adjuvant/adverse effects
  • Humans
  • Middle Aged
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Neoplasm Grading
  • Time Factors
  • Female
  • Radiotherapy, Adjuvant
  • Europe
  • Risk Factors
  • Gynecologic Surgical Procedures/adverse effects
  • Treatment Outcome
  • Endometrial Neoplasms/mortality
  • New Zealand
  • Canada
  • Cisplatin/administration & dosage
  • Dose Fractionation, Radiation
  • Paclitaxel/administration & dosage
  • Carboplatin/administration & dosage
  • Aged
  • Australia
  • Neoplasm Staging
  • Carcinoma, Endometrioid/mortality

Cite this

de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M-H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D., ... PORTEC Study Grp (2018). Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet oncology, 19(3), 295-309. https://doi.org/10.1016/S1470-2045(18)30079-2